SCHAUMBURG, Ill.--(BUSINESS WIRE)--Jun 29, 2026--
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Norepinephrine Bitartrate Injection, USP in the United States as a therapeutic generic equivalent for Levophed ®, as approved by the U.S. Food and Drug Administration. Norepinephrine Bitartrate Injection, USP is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine Bitartrate Injection, USP is available as a carton of ten 4 mg per 4 mL (1 mg per mL) single-dose vials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629726300/en/
In line with Avenacy’s mission to champion patient safety and streamline patient care, Norepinephrine Bitartrate Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Norepinephrine Bitartrate Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
Norepinephrine Bitartrate Injection, USP had U.S. sales of approximately $20 million for the twelve months ending in March 2026.¹
Please see link for Full Prescribing Information.
Levophed ® is a registered trademark of Pfizer Inc.
¹Source: IQVIA
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the company is building a pipeline of high-quality, FDA-approved injectable products to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, a commitment to quality and reliability, and product offerings designed to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit www.avenacy.com.
Avenacy Announces Launch of Norepinephrine Bitartrate Injection, USP in the U.S. Market
WASHINGTON (AP) — The Supreme Court on Monday rejected a push by President Donald Trump to throw out a jury’s finding that he sexually abused the writer E. Jean Carroll at a New York City department store in the mid-1990s and later defamed her.
The high court declined to take up the case in a brief, unexplained order, as is typical. There were no noted dissents.
Trump’s lawyers had argued that allegations leading to the $5 million verdict were propped up by “highly inflammatory” evidentiary rulings, including those that allowed the testimony of two other women who accused Trump of sexual abuse decades ago. Trump has denied all three women’s allegations.
Trump's attorneys argued the judge broke federal evidence rules in the case. They framed it as a distraction from Trump’s unique duties as president, though the verdict came before his return to the White House.
“This mistreatment of a President cannot be allowed to stand,” Attorney Justin D. Smith wrote in court documents. Trump, a Republican, has since nominated Smith to be an appeals court judge.
The decision comes as the court hands down opinions in the biggest cases of the term, many key to Trump's agenda. Trump has publicly vented his frustration with Supreme Court losses in highly personal terms before, including unusual and highly personal criticism when the majority struck down global tariffs he imposed under an emergency powers law.
In a statement reacting to Monday's decision, Trump’s legal team said: “The American People stand with President Trump as they demand an immediate end to all of the Witch Hunts, including the Democrat-funded travesty of the Carroll Hoaxes. President Trump will keep winning against Liberal Lawfare, as he continues to focus on his mission to Make America Great Again.”
Carroll's lawyers had urged the justices to pass on the case. They argued that the women's testimony was relevant because the allegations were similar and that Judge Lewis Kaplan’s decisions were in line with others around the country. “This question is not worthy of review,” wrote attorney Roberta Kaplan, who is not related to the judge.
In a statement Monday, she said the decision affirms the jury's verdict will stand. “His multiple efforts to appeal that verdict have all failed and today’s ruling ends his quest to avoid accountability for his actions,” she said.
Carroll, a longtime advice columnist and former TV talk show host, testified at a 2023 trial that Trump turned a friendly encounter in spring 1996 into a violent attack in the dressing room at Bergdorf Goodman, a luxury retailer across the street from Trump Tower in Manhattan. The jury also found Trump liable for defaming Carroll when he denied her allegation in 2022.
The Associated Press does not identify people who say they have been sexually assaulted unless they come forward publicly, as Carroll has done.
A jury also awarded Carroll an additional $83.3 million after a second defamation trial. Trump also plans to appeal that ruling to the high court, his attorneys have said.
Trump has successfully fended off other hefty court judgments, including a New York civil fraud penalty of over $500 million thrown out by a New York appeals court. The Supreme Court also granted him broad immunity from criminal prosecution in 2024, though it later narrowly rejected his bid to halt sentencing in his New York hush money case.
Associated Press writers Jennifer Peltz in New York and Michelle Price in Washington contributed to this report.
Follow the AP's coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
FILE - E. Jean Carroll arrives at Manhattan federal court, Jan. 17, 2024, in New York. (AP Photo/Eduardo Munoz Alvarez)
FILE - The U.S. Supreme Court is seen, June 11, 2026, in Washington. (AP Photo/Mariam Zuhaib, File)
